Literature DB >> 30938713

Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer.

Victoria H Cruz1, Emily N Arner1, Wenting Du1, Alberto E Bremauntz2, Rolf A Brekken1,3.   

Abstract

Pancreatic ductal adenocarcinoma (PDA) is characterized by an activating mutation in KRAS. Direct inhibition of KRAS through pharmacological means remains a challenge; however, targeting key KRAS effectors has therapeutic potential. We investigated the contribution of TANK-binding kinase 1 (TBK1), a critical downstream effector of mutant active KRAS, to PDA progression. We report that TBK1 supports the growth and metastasis of KRAS-mutant PDA by driving an epithelial plasticity program in tumor cells that enhances invasive and metastatic capacity. Further, we identify that the receptor tyrosine kinase Axl induces TBK1 activity in a Ras-RalB-dependent manner. These findings demonstrate that TBK1 is central to an Axl-driven epithelial-mesenchymal transition in KRAS-mutant PDA and suggest that interruption of the Axl-TBK1 signaling cascade above or below KRAS has potential therapeutic efficacy in this recalcitrant disease.

Entities:  

Keywords:  Cancer; Oncology

Year:  2019        PMID: 30938713      PMCID: PMC6538328          DOI: 10.1172/jci.insight.126117

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  51 in total

1.  Activation of RalA is critical for Ras-induced tumorigenesis of human cells.

Authors:  Kian-Huat Lim; Antonio T Baines; James J Fiordalisi; Michail Shipitsin; Larry A Feig; Adrienne D Cox; Channing J Der; Christopher M Counter
Journal:  Cancer Cell       Date:  2005-06       Impact factor: 31.743

2.  Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells.

Authors:  Kwang M Lee; Hiroaki Yasuda; Michael A Hollingsworth; Michel M Ouellette
Journal:  Lab Invest       Date:  2005-08       Impact factor: 5.662

Review 3.  Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways.

Authors:  Lionel Larue; Alfonso Bellacosa
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

Review 4.  Breast cancer metastasis: markers and models.

Authors:  Britta Weigelt; Johannes L Peterse; Laura J van 't Veer
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

Review 5.  Pancreatic cancer biology and genetics.

Authors:  Nabeel Bardeesy; Ronald A DePinho
Journal:  Nat Rev Cancer       Date:  2002-12       Impact factor: 60.716

6.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

Authors:  Sunil R Hingorani; Lifu Wang; Asha S Multani; Chelsea Combs; Therese B Deramaudt; Ralph H Hruban; Anil K Rustgi; Sandy Chang; David A Tuveson
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

7.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

8.  Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway.

Authors:  Christian Korherr; Hendrik Gille; Rolf Schäfer; Kerstin Koenig-Hoffmann; Johan Dixelius; Kristi A Egland; Ira Pastan; Ulrich Brinkmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

9.  The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines.

Authors:  Sylvia Julien Grille; Alfonso Bellacosa; John Upson; Andres J Klein-Szanto; Frans van Roy; Whaseon Lee-Kwon; Mark Donowitz; Philip N Tsichlis; Lionel Larue
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

10.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

Authors:  Sunil R Hingorani; Emanuel F Petricoin; Anirban Maitra; Vinodh Rajapakse; Catrina King; Michael A Jacobetz; Sally Ross; Thomas P Conrads; Timothy D Veenstra; Ben A Hitt; Yoshiya Kawaguchi; Don Johann; Lance A Liotta; Howard C Crawford; Mary E Putt; Tyler Jacks; Christopher V E Wright; Ralph H Hruban; Andrew M Lowy; David A Tuveson
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

View more
  13 in total

1.  AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer.

Authors:  Yuqing Zhang; Emily N Arner; Ali Rizvi; Jason E Toombs; Huocong Huang; Steven L Warner; Jason M Foulks; Rolf A Brekken
Journal:  Mol Cancer Ther       Date:  2021-10-21       Impact factor: 6.009

Review 2.  Targeting TANK-binding kinase 1 (TBK1) in cancer.

Authors:  Or-Yam Revach; Shuming Liu; Russell W Jenkins
Journal:  Expert Opin Ther Targets       Date:  2020-10-05       Impact factor: 6.902

3.  Modeling EV Kinetics for Use in Early Cancer Detection.

Authors:  Scott Ferguson; Ralph Weissleder
Journal:  Adv Biosyst       Date:  2020-05-12

4.  AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer.

Authors:  Wenting Du; Natalie Z Phinney; Huocong Huang; Zhaoning Wang; Jill Westcott; Jason E Toombs; Yuqing Zhang; Muhammad S Beg; Thomas M Wilkie; James B Lorens; Rolf A Brekken
Journal:  Mol Cancer Res       Date:  2021-04-02       Impact factor: 5.852

5.  Macrophage AXL receptor tyrosine kinase inflames the heart after reperfused myocardial infarction.

Authors:  Matthew DeBerge; Kristofor Glinton; Manikandan Subramanian; Lisa D Wilsbacher; Carla V Rothlin; Ira Tabas; Edward B Thorp
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

6.  TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration.

Authors:  Yuchuan Jiang; Siliang Chen; Qiang Li; Junjie Liang; Weida Lin; Jinying Li; Zhilong Liu; Mingbo Wen; Mingrong Cao; Jian Hong
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

7.  TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss.

Authors:  Lianxin Hu; Haibiao Xie; Xijuan Liu; Frances Potjewyd; Lindsey I James; Emily M Wilkerson; Laura E Herring; Ling Xie; Xian Chen; Johnny Castillo Cabrera; Kai Hong; Chengheng Liao; Xianming Tan; Albert S Baldwin; Kan Gong; Qing Zhang
Journal:  Cancer Discov       Date:  2019-12-06       Impact factor: 38.272

Review 8.  Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment.

Authors:  Mai Tanaka; Dietmar W Siemann
Journal:  Cancers (Basel)       Date:  2020-07-09       Impact factor: 6.575

Review 9.  Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers.

Authors:  Emily N Arner; Wenting Du; Rolf A Brekken
Journal:  Front Oncol       Date:  2019-10-11       Impact factor: 6.244

10.  WNK1 Enhances Migration and Invasion in Breast Cancer Models.

Authors:  Ankita B Jaykumar; Ji-Ung Jung; Pravat Kumar Parida; Tuyen T Dang; Chonlarat Wichaidit; Ashari Rashmi Kannangara; Svetlana Earnest; Elizabeth J Goldsmith; Gray W Pearson; Srinivas Malladi; Melanie H Cobb
Journal:  Mol Cancer Ther       Date:  2021-07-12       Impact factor: 6.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.